Leukemia Research
Volume 29, Issue 7 , Pages 727-728 , July 2005

Combined targeting of the epigenetic silence in leukemia: Cooperating activities of DNA methylation and histone deacetylation inhibitors

Received 3 January 2005

References 

  1. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2000;134:573
  2. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429
  3. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956
  4. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol. 2001;114:34
  5. Burgers WA, Fuks F, Kouzarides T. DNA methyltransferases get connected to chromatin. Trends Genet. 2002;18:275
  6. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2001;7:2330
  7. Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res. 2004;10:4589
  8. Jahangeer S, Elliott RM, Henneberry RC. Beta-adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate. Biochem Biophys Res Commun. 1982;108:1434
  9. Cameron EE, Bachman KE, Myohänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103
  10. Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969
  11. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734
  12. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266
  13. Guel H, Wassmann B, Romanski A, Hoelzer D, Ruthardt M, Ottmann OG, et al. Effect of the histone deacetylase inhibitor valproic acid in combination with all-trans retinoic acid on normal and malignant hematopoiesis. Blood. 2003;102(Suppl.):626a
  14. Schmid M, Fröhling S, Schlenk RF, Döhner H. Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) with the histone deacetylase inhibitor valproic acid (VPA) in combination with all-trans retinoic acid (ATRA). Onkologie. 2004;27(Suppl. 3):83
  15. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian J, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deocycytidine with valproic acid. Leuk Res. 2005;29:738
  16. Garcia-Manero G, Kantarjian H, Sanchez-Gonzales B, Faderl S, Verstovsek S, Ravandi F, et al. Results of a phase I/II study of the combination of 5-aza-2′deocycytidine (DAC) with valproic acid (VPA) in patients with leukemia. Blood. 2004;104(Suppl.):78a
  17. Gore SD, Baylin SB, Dauses T, Grever MR, Jiemjit A, Manning J, et al. Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacytidine and sodium phenylbutyrate. Blood. 2004;104(Suppl.):137a

PII: S0145-2126(05)00164-5

doi: 10.1016/j.leukres.2005.01.021

Leukemia Research
Volume 29, Issue 7 , Pages 727-728 , July 2005

Article Tools